Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048022 · ClinicalTrials.gov registry record · Phase 2
Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00048022: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00048022 is a Phase 2 study that has completed, run by Hoffmann-La Roche. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048022, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The primary objective of the study is to evaluate the anti-inflammatory action and safety of Ro 27-2441 (study drug) in asthmatic patients currently taking inhaled corticosteroids. The research is being conducted at up to 40 clinical research sites in the US. Study participants will have a number of visits to a research site over a 4-month period.
Interventions
- DRUG Dual Integrin Antagonist
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10-25 |
| Est. Completion | 2004-02-02 |
| Phase | Phase 2 |
What the finished NCT00048022 record still lists
NCT00048022 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Dual Integrin Antagonist is the first listed.
NCT00048022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00048022 about?
NCT00048022 is a clinical study titled "Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma". The primary objective of the study is to evaluate the anti-inflammatory action and safety of Ro 27-2441 (study drug) in asthmatic patients currently taking inhaled corticosteroids. The research is being conducted at up to 40 clinical research sites in the US. Study participants will have a number of...
What is the current status of trial NCT00048022?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-10-25. Estimated completion is 2004-02-02.
What interventions are being tested in trial NCT00048022?
The interventions under investigation include: Dual Integrin Antagonist (DRUG).
Who is sponsoring clinical trial NCT00048022?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI